Gainers
- Agape ATP (NASDAQ:ATPC) shares rose 75.2% to $0.12 during Thursday's regular session. The company's market cap stands at $3.4 million.
- HeartBeam (NASDAQ:BEAT) stock rose 50.0% to $2.33. The market value of their outstanding shares is at $53.3 million.
- NexGel (NASDAQ:NXGL) shares rose 29.33% to $1.94. The market value of their outstanding shares is at $12.2 million.
- CapsoVision (NASDAQ:CV) stock increased by 18.64% to $14.0. The market value of their outstanding shares is at $552.7 million.
- TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 17.96% to $10.18. The market value of their outstanding shares is at $7.9 million.
- GridAI Technologies (NASDAQ:GRDX) stock rose 16.53% to $3.03. The company's market cap stands at $8.7 million.
Losers
- Rezolute (NASDAQ:RZLT) stock fell 88.6% to $1.25 during Thursday's regular session. The company's market cap stands at $1.0 billion.
- GRI Bio (NASDAQ:GRI) stock declined by 54.07% to $0.56. The company's market cap stands at $3.9 million.
- Pomdoctor (NASDAQ:POM) shares decreased by 29.06% to $0.35. The market value of their outstanding shares is at $59.5 million.
- XOMA Royalty (NASDAQ:XOMA) shares declined by 22.3% to $26.7. The company's market cap stands at $425.4 million.
- Inspire Veterinary (NASDAQ:IVP) stock decreased by 16.81% to $0.05. The market value of their outstanding shares is at $2.3 million.
- WAVE Life Sciences (NASDAQ:WVE) shares decreased by 16.69% to $16.86. The company's market cap stands at $3.3 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BEATHeartBeam Inc
$2.4255.8%
CVCapsoVision Inc
$14.3921.9%
GRDXGridAI Technologies Corp
$2.9714.2%
GRIGRI Bio Inc
$0.5546-54.2%
IVPInspire Veterinary Partners Inc
$0.0527-13.2%
NXGLNexGel Inc
$1.8926.0%
POMPomdoctor Ltd
$0.3700-26.0%
RNAZTransCode Therapeutics Inc
$10.1818.0%
RZLTRezolute Inc
$1.19-89.2%
WVEWAVE Life Sciences Ltd
$16.95-16.2%
XOMAXOMA Royalty Corp
$26.70-22.3%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

